Olympus has announced the launch of sensitive and precise PSA and fPSA assays for the Olympus AU3000i immunoassay analyser.
The PSA assay has a functional sensitivity of 0.015ug/L.
The Olympus PSA and fPSA assays utilise a two-step immunometric design.
This minimises the risk of high-dose-hook, ensuring that even the measurement of samples with highly elevated PSA levels will generate appropriate results.
No high-dose-hook has been observed at PSA concentrations up to 160.000ug/L.
A multicentre evaluation of the analytical performance of the Olympus PSA assay on the AU3000i has been undertaken involving the University Hospital Munich Grosshadern, the Hospital Nurnberg, and the CHU Montpellier.
The study demonstrated that the Olympus PSA assay showed good functional sensitivity and is suitable for use in the quantitative determination of PSA in human serum and lithium heparin plasma.
With the launch of both PSA and fPSA, Olympus completes another test panel for the AU3000i.
The primary tumour marker panel includes AFP, CEA, PSA, and fPSA - these assays account for approximately 70 per cent of the tumour marker workload performed in a laboratory.
Olympus also offers the specialist tumour markers GI-TC and BR-TC, and further tumour markers are planned for the future.
